STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds
Many large pharmaceutical companies are taking steps to improve access to their medicines in low- and middle-income countries, but progress has been mixed and more action is needed to ensure wide availability, a new analysis found.
Key points
- And across the pipeline, 95% of late-stage experimental drugs developed with a nonprofit partner have an access plan in place, versus 67% without such a partner.
- Continue to STAT+ to read the full story….
But 43% of access plans for non-communicable diseases — specifically, sickle cell disease, diabetes, and mental health — focus solely on regulatory registrations and primarily in wealthy countries.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.